Biocompatibility of cardiopulmonary bypass circuit with new polymer Senko E-Ternal Coating TM

Abstract

Objective:

The aim of this study was to compare the biocompatibility of a new Senko E-Ternal coating (SEC) for cardiopulmonary bypass (CPB) circuits with the well-established poly-2-methoxyethyl acrylate (PMEA) coating.

Methods:

Forty patients undergoing aortic valve replacement were randomly assigned to either an SEC-coated group (n = 20) or a PMEA-coated group (n = 20). Clinical data and the following markers were analyzed: platelet count, platelet factor (PF) 4, fibrinogen, fibrinogen degradation products (FDPs), antithrombin III (AT III), thrombin-antithrombin complex (TAT), plasminogen, complement hemolytic activity (CH50), complement 3 (C3) and interleukin-6 (IL-6). Blood samples were obtained at five time points in both groups.

Results:

CPB time, aortic cross-clamp time and blood loss and transfusion were similar in both groups. There were no significant differences between the groups in terms of platelet count, PF4 and all coagulation and fibrinolytic parameters (FDP, AT III, TAT, and plasminogen) at any time points. Inflammatory markers (CH50, C3 and IL-6) were also similar in both groups at all time points.

Conclusions:

The SEC-coated circuit demonstrated equivalent biocompatibility to the PMEA-coated circuit. SEC-coated circuits are, therefore, favorably comparable to PMEA-coated circuits for clinical use in CPB.

Keywords

biocompatible coatings cardiopulmonary bypass cardiovascular surgery inflammatory response

Get full access to this article

View all access options for this article.

References

Raja

Dreyfus

. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann 2005; 13: 382–395.

Shann

Likosky

Murkin

. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 2006; 132: 283–290.

Jansen

Baufreton

Le Besnerais

. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 1996; 61: 1363–1366.

te Velthuis

Baufreton

Jansen

. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg 1997; 114: 117–122.

Lundblad

Moen

Fosse

. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 1361–1367.

Fosse

Thelin

Svennevig

. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg 1997; 11: 320–327.

Ranucci

Mazzucco

Pessotto

. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999; 67: 994–1000.

Belboul

Lofgren

Storm

. Heparin-coated circuits reduce occult myocardial damage during CPB: a randomized, single blind clinical trial. Eur J Cardiothorac Surg 2000; 17: 580–586.

Khuri

Valeri

Loscalzo

. Heparin causes platelet dysfunction and increases fibrinolysis before the institution of cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008–1014.

10.

Sobel

McNeill

Carlson

. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787–1793.

11.

Silvetti

Koster

Pappalardo

. Do we need heparin coating for extracorporeal membrane oxygenation? New concepts and controversial positions about coating surfaces of extracorporeal circuits. Artif Organs 2015; 39: 176-179.

12.

Baykut

Bernet

Wehrle

. New surface biopolymers for oxygenators: an in vitro hemocompatibility test of poly (2-methoxyethlacrylate). Eur J Med Res 2001; 6: 297–305.

13.

Saito

Motoyama

Sawamoto

. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif Organs 2000; 24: 547–554.

14.

Ninomiya

Miyaji

Takamoto

. Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg 2003; 75: 913–917.

15.

Ikuta

Fujii

Shibata

. A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. Ann Thorac Surg 2004; 77: 1678–1683.

16.

Suzuki

Daitoku

Minakawa

. Poly-2-methoxyethylacrylate-coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery. J Artif Organs 2008; 11: 111–116.

17.

Kirklin

Westaby

Blackstone

. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845–857.

18.

Ascione

Lloyd

Underwood

. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 2000; 69: 1198–1204.

19.

Lamba

Courtney

. Polymeric biomaterials: influence of phosphorylcholine polar groups on protein adsorption and complement activation. Int J Artif Organs 1994; 17: 499–504.

20.

Van

Caes

. Phosphorylcholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion 2002; 17: 39–44.

21.

Böning

Scheewe

Ivers

. Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants. J Thorac Cardiovasc Surg 2004; 127: 1458–1465.

22.

Thiara

Mollnes

Videm

. Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery. Perfusion 2011; 26: 107–114.

23.

Reser

Seifert

Klein

. Retrospective analysis of outcome data with regard to the use of Phisio^®-, Bioline^®- or Softline^®-coated cardiopulmonary bypass circuits in cardiac surgery. Perfusion 2012; 27: 530–534.

24.

Zilla

Fasol

Groscurth

. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379–388.

25.

Izuha

Hattori

Igari

. Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material. J Artif Organs 2005; 8: 41–46.

26.

Edmunds

. Cardiopulmonary bypass after 50 years. N Engl J Med 2004; 351: 1603–1606.

27.

Levy

Tanaka

. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715–720.

28.

Sower

Froelich

Carney

. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995; 155: 895–901.

29.

Edmunds

Jr Colman

. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 2006; 82: 2315–2322.